Declaration of interests RL serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse Bio, Inipharma, Intercept, Inventiva, Ionis, Janssen, Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89Bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. RL has stock options in Sagimet Biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes, and Terns Pharmaceuticals. He is a co-founder of LipoNexus. RL receives funding support from the National Institute of Diabetes and Digestive and Kidney Diseases (P30DK120515) and the John C Martin Foundation (RP124). KG, EBM, GK, MO'F, WM, and W-WT are current or former employees of Sagimet Biosciences and own or have options to purchase stock in the company. EL is a researcher for 89Bio, Akero Therapeutics, Alnylam Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, DSM, Eli Lilly, Enanta Pharmaceuticals, Enyo Pharma, Exalenz Bioscience, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead Sciences, GSK, Hanmi Pharmaceuticals, Hightide Biopharma, Intercept Pharmaceuticals, Inventiva, Janssen Pharmaceuticals, Madrigal Pharmaceuticals, Merck & Co, NGM Biopharmaceuticals, Northsea Therapeutics, Novartis, Novo Nordisk, Poxel, Sagimet Biosciences, Takeda, Terns Pharmaceuticals, Viking Therapeutics, and Zydus Pharmaceuticals. SAH was a scientific advisor or consultant for Akero, Aligos, Altimmune, Arrowhead, Auransa, Echosens, Galecto, Gilead, GSK, Hepion, Hepta Bio, HistoIndex, Humana, Inventiva, Kriya, Madrigal, Medpace, Merck, NeuroBo, Northsea, Novo Nordisk, Perspectum, Pfizer, Seal Rock, Sonic Incytes, Sagimet, Terns, and Viking. They received grant or research support from Akero, Altimmune, Axcella, BMS, Corcept, Cymabay, Enyo, Galectin, Genentech, Genfit, Gilead, GSK, Hepion, Hightide, Immuron, Intercept, Inventiva, Ionis, Madrigal, NGM Bio, Novartis, Novo Nordisk, Northsea, Pfizer, Poxel, Sagimet, Terns, and Viking. All other authors declare no competing interests.
PubMed
